These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 7581424)

  • 21. A population pharmacokinetic model with time-dependent covariates measured with errors.
    Li L; Lin X; Brown MB; Gupta S; Lee KH
    Biometrics; 2004 Jun; 60(2):451-60. PubMed ID: 15180671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The back-step method--method for obtaining unbiased population parameter estimates for ordered categorical data.
    Kjellsson MC; Jönsson S; Karlsson MO
    AAPS J; 2004 Aug; 6(3):e19. PubMed ID: 15760104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimation of pharmacokinetic parameters from non-compartmental variables using Microsoft Excel.
    Dansirikul C; Choi M; Duffull SB
    Comput Biol Med; 2005 Jun; 35(5):389-403. PubMed ID: 15767115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparing the performance of FOCE and different expectation-maximization methods in handling complex population physiologically-based pharmacokinetic models.
    Liu X; Wang Y
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):359-70. PubMed ID: 27215925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients.
    Irtan S; Saint-Marcoux F; Rousseau A; Zhang D; Leroy V; Marquet P; Jacqz-Aigrain E
    Ther Drug Monit; 2007 Feb; 29(1):96-102. PubMed ID: 17304156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simultaneous versus sequential pharmacokinetic-pharmacodynamic population analysis using an iterative two-stage Bayesian technique.
    Proost JH; Schiere S; Eleveld DJ; Wierda JM
    Biopharm Drug Dispos; 2007 Nov; 28(8):455-73. PubMed ID: 17847121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bayesian hierarchical modeling of receptor occupancy in PET trials.
    Vandenhende F; Renard D; Nie Y; Kumar A; Miller J; Tauscher J; Witcher J; Zhou Y; Wong DF
    J Biopharm Stat; 2008; 18(2):256-72. PubMed ID: 18327720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic parameters estimation using adaptive Bayesian P-splines models.
    Jullion A; Lambert P; Beck B; Vandenhende F
    Pharm Stat; 2009; 8(2):98-112. PubMed ID: 18481279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction discrepancies for the evaluation of nonlinear mixed-effects models.
    Mentré F; Escolano S
    J Pharmacokinet Pharmacodyn; 2006 Jun; 33(3):345-67. PubMed ID: 16284919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. REML estimation of variance parameters in nonlinear mixed effects models using the SAEM algorithm.
    Meza C; Jaffrézic F; Foulley JL
    Biom J; 2007 Dec; 49(6):876-88. PubMed ID: 17638294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration.
    Salinger DH; Vicini P; Blough DK; O'Donnell PV; Pawlikowski MA; McCune JS
    J Clin Pharmacol; 2010 Nov; 50(11):1292-300. PubMed ID: 20075185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modeling attainment of steady state of drug concentration in plasma by means of a Bayesian approach using MCMC methods.
    Jordan P; Brunschwig H; Luedin E
    Pharm Stat; 2008; 7(1):36-41. PubMed ID: 17335108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Considerations in analyzing single-trough concentrations using mixed-effects modeling.
    Booth BP; Gobburu JV
    J Clin Pharmacol; 2003 Dec; 43(12):1307-15. PubMed ID: 14615466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of nonlinear mixed-model analyses for a pediatric pharmacokinetic study.
    Hartford A; Migoya E; Maganti L; Porras A; Zhang J
    J Biopharm Stat; 2005; 15(3):465-78. PubMed ID: 15920891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two-level time-domain decomposition based distributed method for numerical solutions of pharmacokinetic models.
    Liu L; Lai CH; Zhou SD; Xie F; Rui L
    Comput Biol Med; 2011 Apr; 41(4):221-7. PubMed ID: 21396631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Comparative pharmacokinetic analysis based on nonlinear mixed effect model].
    Li LJ; Li XX; Xu L; Lü YH; Chen JC; Zheng QS
    Yao Xue Xue Bao; 2011 Apr; 46(4):447-53. PubMed ID: 21751499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A general method to determine sampling windows for nonlinear mixed effects models with an application to population pharmacokinetic studies.
    Foo LK; McGree J; Duffull S
    Pharm Stat; 2012; 11(4):325-33. PubMed ID: 22411749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Further developments of the Fisher information matrix in nonlinear mixed effects models with evaluation in population pharmacokinetics.
    Retout S; Mentré F
    J Biopharm Stat; 2003 May; 13(2):209-27. PubMed ID: 12729390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimation of the shelf-life of drugs with mixed effects models.
    Chen JJ; Hwang JS; Tsong Y
    J Biopharm Stat; 1995 Mar; 5(1):131-40. PubMed ID: 7613558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An alternative two stage method via the EM-algorithm for the estimation of population pharmacokinetic parameters.
    Amisaki T; Tatsuhara T
    J Pharmacobiodyn; 1988 May; 11(5):335-48. PubMed ID: 3171876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.